NZ616149B2 - Nasal Pharmaceutical Formulation Comprising Fluticasone - Google Patents
Nasal Pharmaceutical Formulation Comprising Fluticasone Download PDFInfo
- Publication number
- NZ616149B2 NZ616149B2 NZ616149A NZ61614912A NZ616149B2 NZ 616149 B2 NZ616149 B2 NZ 616149B2 NZ 616149 A NZ616149 A NZ 616149A NZ 61614912 A NZ61614912 A NZ 61614912A NZ 616149 B2 NZ616149 B2 NZ 616149B2
- Authority
- NZ
- New Zealand
- Prior art keywords
- formulation
- fluticasone
- nasal
- droplets
- treatment
- Prior art date
Links
- 239000008194 pharmaceutical composition Substances 0.000 title claims abstract description 4
- MGNNYOODZCAHBA-GQKYHHCASA-N Fluticasone Chemical compound C1([C@@H](F)C2)=CC(=O)C=C[C@]1(C)[C@]1(F)[C@@H]2[C@@H]2C[C@@H](C)[C@@](C(=O)SCF)(O)[C@@]2(C)C[C@@H]1O MGNNYOODZCAHBA-GQKYHHCASA-N 0.000 title abstract description 20
- 229960002714 fluticasone Drugs 0.000 title abstract description 20
- 239000000203 mixture Substances 0.000 claims abstract description 29
- 238000009472 formulation Methods 0.000 claims abstract description 24
- PEDCQBHIVMGVHV-UHFFFAOYSA-N glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims abstract description 18
- WRMNZCZEMHIOCP-UHFFFAOYSA-N Phenethyl alcohol Chemical compound OCCC1=CC=CC=C1 WRMNZCZEMHIOCP-UHFFFAOYSA-N 0.000 claims abstract description 10
- 229920000168 Microcrystalline cellulose Polymers 0.000 claims abstract description 8
- 235000019813 microcrystalline cellulose Nutrition 0.000 claims abstract description 8
- 229940068968 Polysorbate 80 Drugs 0.000 claims abstract description 7
- 239000001768 carboxy methyl cellulose Substances 0.000 claims abstract description 7
- 239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 claims abstract description 7
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 claims abstract description 7
- 229920000053 polysorbate 80 Polymers 0.000 claims abstract description 7
- ZGTMUACCHSMWAC-UHFFFAOYSA-L disodium;2-[2-[carboxylatomethyl(carboxymethyl)amino]ethyl-(carboxymethyl)amino]acetate Chemical compound [Na+].[Na+].OC(=O)CN(CC([O-])=O)CCN(CC(O)=O)CC([O-])=O ZGTMUACCHSMWAC-UHFFFAOYSA-L 0.000 claims abstract description 6
- 239000008108 microcrystalline cellulose Substances 0.000 claims abstract description 6
- 229940016286 microcrystalline cellulose Drugs 0.000 claims abstract description 6
- 230000001932 seasonal Effects 0.000 claims abstract description 6
- 229940067107 Phenylethyl Alcohol Drugs 0.000 claims abstract description 5
- 230000000172 allergic Effects 0.000 claims abstract description 5
- 201000008937 atopic dermatitis Diseases 0.000 claims abstract description 5
- 230000000069 prophylaxis Effects 0.000 claims abstract description 5
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 claims abstract description 3
- 239000007921 spray Substances 0.000 claims description 11
- 229920002134 Carboxymethyl cellulose Polymers 0.000 claims description 6
- 229940105329 Carboxymethylcellulose Drugs 0.000 claims description 6
- 235000010948 carboxy methyl cellulose Nutrition 0.000 claims description 6
- 239000008112 carboxymethyl-cellulose Substances 0.000 claims description 6
- XBDQKXXYIPTUBI-UHFFFAOYSA-M propionate Chemical compound CCC([O-])=O XBDQKXXYIPTUBI-UHFFFAOYSA-M 0.000 claims description 5
- VEXZGXHMUGYJMC-UHFFFAOYSA-M chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 claims description 4
- 239000003814 drug Substances 0.000 claims description 4
- 239000002738 chelating agent Substances 0.000 claims description 3
- 230000002335 preservative Effects 0.000 claims description 3
- 239000003755 preservative agent Substances 0.000 claims description 3
- 239000000126 substance Substances 0.000 claims description 3
- 239000000375 suspending agent Substances 0.000 claims description 3
- 239000000080 wetting agent Substances 0.000 claims description 3
- 206010010741 Conjunctivitis Diseases 0.000 claims description 2
- WMWTYOKRWGGJOA-CENSZEJFSA-N Fluticasone propionate Chemical compound C1([C@@H](F)C2)=CC(=O)C=C[C@]1(C)[C@]1(F)[C@@H]2[C@@H]2C[C@@H](C)[C@@](C(=O)SCF)(OC(=O)CC)[C@@]2(C)C[C@@H]1O WMWTYOKRWGGJOA-CENSZEJFSA-N 0.000 abstract description 10
- 229960000289 fluticasone propionate Drugs 0.000 abstract description 9
- 206010039085 Rhinitis allergic Diseases 0.000 abstract description 7
- 201000010105 allergic rhinitis Diseases 0.000 abstract description 7
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 abstract description 4
- 229960000686 Benzalkonium Chloride Drugs 0.000 abstract description 3
- 206010010744 Conjunctivitis allergic Diseases 0.000 abstract description 3
- 229960005150 glycerol Drugs 0.000 abstract 1
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 abstract 1
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 abstract 1
- 206010020751 Hypersensitivity Diseases 0.000 description 8
- 201000005794 allergic hypersensitivity disease Diseases 0.000 description 8
- 239000004480 active ingredient Substances 0.000 description 7
- 239000003246 corticosteroid Substances 0.000 description 7
- 239000011780 sodium chloride Substances 0.000 description 7
- 150000002148 esters Chemical class 0.000 description 6
- 150000003839 salts Chemical class 0.000 description 6
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 5
- JZUFKLXOESDKRF-UHFFFAOYSA-N Dichlothiazide Chemical compound C1=C(Cl)C(S(=O)(=O)N)=CC2=C1NCNS2(=O)=O JZUFKLXOESDKRF-UHFFFAOYSA-N 0.000 description 3
- 229940097496 Nasal Spray Drugs 0.000 description 3
- 206010028735 Nasal congestion Diseases 0.000 description 3
- 229960001716 benzalkonium Drugs 0.000 description 3
- WVDDGKGOMKODPV-UHFFFAOYSA-N benzyl alcohol Chemical compound OCC1=CC=CC=C1 WVDDGKGOMKODPV-UHFFFAOYSA-N 0.000 description 3
- CYDRXTMLKJDRQH-UHFFFAOYSA-N benzyl-dodecyl-dimethylazanium Chemical compound CCCCCCCCCCCC[N+](C)(C)CC1=CC=CC=C1 CYDRXTMLKJDRQH-UHFFFAOYSA-N 0.000 description 3
- 239000007922 nasal spray Substances 0.000 description 3
- 239000008213 purified water Substances 0.000 description 3
- 238000003756 stirring Methods 0.000 description 3
- 229940064701 Corticosteroid nasal preparations for topical use Drugs 0.000 description 2
- 229960001334 Corticosteroids Drugs 0.000 description 2
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 2
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 2
- 208000000592 Nasal Polyps Diseases 0.000 description 2
- 206010052437 Nasal discomfort Diseases 0.000 description 2
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 2
- 206010039083 Rhinitis Diseases 0.000 description 2
- 235000014113 dietary fatty acids Nutrition 0.000 description 2
- 239000006185 dispersion Substances 0.000 description 2
- 229940009662 edetate Drugs 0.000 description 2
- KCXVZYZYPLLWCC-UHFFFAOYSA-N edta Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 239000000194 fatty acid Substances 0.000 description 2
- 150000004665 fatty acids Chemical class 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- 125000000286 phenylethyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])([H])* 0.000 description 2
- -1 polyoxyethylene Polymers 0.000 description 2
- DNIAPMSPPWPWGF-UHFFFAOYSA-N propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 239000000600 sorbitol Substances 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 229940083878 topical for treatment of hemorrhoids and anal fissures Corticosteroids Drugs 0.000 description 2
- 125000004343 1-phenylethyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 206010001076 Acute sinusitis Diseases 0.000 description 1
- 208000006673 Asthma Diseases 0.000 description 1
- 229940092705 Beclomethasone Drugs 0.000 description 1
- 230000036912 Bioavailability Effects 0.000 description 1
- 229960004436 Budesonide Drugs 0.000 description 1
- VOVIALXJUBGFJZ-VXKMTNQYSA-N Budesonide Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@@H]2[C@@H]1[C@@H]1C[C@H]3O[C@@H](CCC)O[C@@]3(C(=O)CO)[C@@]1(C)C[C@@H]2O VOVIALXJUBGFJZ-VXKMTNQYSA-N 0.000 description 1
- 229960003260 Chlorhexidine Drugs 0.000 description 1
- 206010009137 Chronic sinusitis Diseases 0.000 description 1
- LUKZNWIVRBCLON-GXOBDPJESA-N Ciclesonide Chemical compound C1([C@H]2O[C@@]3([C@H](O2)C[C@@H]2[C@@]3(C[C@H](O)[C@@H]3[C@@]4(C)C=CC(=O)C=C4CC[C@H]32)C)C(=O)COC(=O)C(C)C)CCCCC1 LUKZNWIVRBCLON-GXOBDPJESA-N 0.000 description 1
- 241000565118 Cordylophora caspia Species 0.000 description 1
- RKHQGWMMUURILY-UHRZLXHJSA-N Cortivazol Chemical compound C([C@H]1[C@@H]2C[C@H]([C@]([C@@]2(C)C[C@H](O)[C@@H]1[C@@]1(C)C2)(O)C(=O)COC(C)=O)C)=C(C)C1=CC1=C2C=NN1C1=CC=CC=C1 RKHQGWMMUURILY-UHRZLXHJSA-N 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N D-Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N D-sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 241001669679 Eleotris Species 0.000 description 1
- GHXZTYHSJHQHIJ-UHFFFAOYSA-N Exidine Chemical compound C=1C=C(Cl)C=CC=1NC(N)=NC(N)=NCCCCCCN=C(N)N=C(N)NC1=CC=C(Cl)C=C1 GHXZTYHSJHQHIJ-UHFFFAOYSA-N 0.000 description 1
- 206010052140 Eye pruritus Diseases 0.000 description 1
- 229940033835 Flonase Drugs 0.000 description 1
- 239000001828 Gelatine Substances 0.000 description 1
- 229940031574 HYDROXYMETHYL CELLULOSE Drugs 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 229960001664 Mometasone Drugs 0.000 description 1
- 210000001331 Nose Anatomy 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 206010061529 Polyp Diseases 0.000 description 1
- 206010039094 Rhinitis perennial Diseases 0.000 description 1
- 206010039101 Rhinorrhoea Diseases 0.000 description 1
- 210000002966 Serum Anatomy 0.000 description 1
- 208000000927 Sleep Apnea Syndrome Diseases 0.000 description 1
- 206010040979 Sleep apnoea syndrome Diseases 0.000 description 1
- 206010041232 Sneezing Diseases 0.000 description 1
- 206010041235 Snoring Diseases 0.000 description 1
- CZMRCDWAGMRECN-GDQSFJPYSA-N Sucrose Natural products O([C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@H](CO)O1)[C@@]1(CO)[C@H](O)[C@@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-GDQSFJPYSA-N 0.000 description 1
- RTKIYNMVFMVABJ-UHFFFAOYSA-L Thiomersal Chemical compound [Na+].CC[Hg]SC1=CC=CC=C1C([O-])=O RTKIYNMVFMVABJ-UHFFFAOYSA-L 0.000 description 1
- 238000009098 adjuvant therapy Methods 0.000 description 1
- 239000003470 adrenal cortex hormone Substances 0.000 description 1
- 150000008064 anhydrides Chemical class 0.000 description 1
- NBMKJKDGKREAPL-DVTGEIKXSA-N beclomethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(Cl)[C@@H]1[C@@H]1C[C@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O NBMKJKDGKREAPL-DVTGEIKXSA-N 0.000 description 1
- 235000019445 benzyl alcohol Nutrition 0.000 description 1
- 230000035514 bioavailability Effects 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 235000010980 cellulose Nutrition 0.000 description 1
- 229960003728 ciclesonide Drugs 0.000 description 1
- QXNVGIXVLWOKEQ-UHFFFAOYSA-N disodium Chemical compound [Na][Na] QXNVGIXVLWOKEQ-UHFFFAOYSA-N 0.000 description 1
- 229940079593 drugs Drugs 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 230000005182 global health Effects 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 229920003063 hydroxymethyl cellulose Polymers 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- QLIIKPVHVRXHRI-CXSFZGCWSA-N mometasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(Cl)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CCl)(O)[C@@]1(C)C[C@@H]2O QLIIKPVHVRXHRI-CXSFZGCWSA-N 0.000 description 1
- 210000004877 mucosa Anatomy 0.000 description 1
- 230000000414 obstructive Effects 0.000 description 1
- 239000002357 osmotic agent Substances 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 201000002859 sleep apnea Diseases 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- 229960004906 thiomersal Drugs 0.000 description 1
- 238000004481 total suppression of sideband Methods 0.000 description 1
- 229920002554 vinyl polymer Polymers 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N β-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0043—Nose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
Abstract
Provided is a nasal pharmaceutical formulation comprising fluticasone. In a preferred embodiment the formulation comprises fluticasone propionate, microcrystalline cellulose, sodium carboxymethylcellulose, disodium edetate, polysorbate 80, glycerol and one or more of benzalkonium chloride or phenylethyl alcohol, wherein the formulation is adapted to be applied as droplets and half of the droplets in the administered dose unit are between 75um and 95 um in size. The formulation may be useful for the prophylaxis or treatment of seasonal or perennial allergic and non-allergic rhinitis, and rhinoconjunctivitis. thyl alcohol, wherein the formulation is adapted to be applied as droplets and half of the droplets in the administered dose unit are between 75um and 95 um in size. The formulation may be useful for the prophylaxis or treatment of seasonal or perennial allergic and non-allergic rhinitis, and rhinoconjunctivitis.
Description
— l —
Nasal pharmaceutical formulation comprising fluticasone
The :present invention relates to a :nasal formulation
sing an intranasal osteroid as active
ingredient. In a preferred embodiment, the invention
relates to a nasal formulation sing fluticasone
or pharmaceutically acceptable esters or salts thereof.
ha a particularly preferred embodiment, the invention
relates to a nasal ation comprising fluticasone
propionate.
The present invention further relates to a method for
the laxis or treatment of seasonal or perennial
allergic and non—allergic rhinitis and
rhinoconjunctivitis and also for the treatment of nasal
polyps, for prophylaxis of polyp recurrence following
surgical removal of nasal polyps, as adjuvant therapy
for acute and chronic sinusitis, for sleep apnea,
snoring or inflammation—related obstructive sleep
ers, with a nasal formulation comprising an
intranasal corticosteroid as active ingredient,
preferably" fluticasone or pharmaceutically' acceptable
esters or salts thereof. SUI a particularly preferred
embodiment, the invention relates to a method for the
prophylaxis or treatment of seasonal or ial
ic rhinitis and rhinoconjunctivitis with a nasal
formulation comprising fluticasone propionate.
The present invention further relates to a method for
preparing a nasal formulation sing an intranasal
corticosteroid as active ingredient, preferably
fluticasone or pharmaceutically acceptable esters or
salts thereof. In a preferred embodiment, the invention
relates to a method for preparing a nasal formulation
sing fluticasone propionate.
Allergic rhinitis is a global health problem with
increasing prevalence. Currently about 500 million
people worldwide are affected by it. Symptoms of
allergic rhinitis affect social life, sleep, the
ability to learn and work and therefore cause
erable stress uet et al., Allergy. 2008
Apr; 63 Suppl 86:8—160).
For patients with er symptoms, particularly nasal
congestion, intranasal corticosteroids are the
treatment of choice (LaForce J .Allergy Clin Immunol
1999; 103; pp. 388-94; Brozek et al., J Allergy Clin
Immunol 2010; 126: , Wallace J Allergy Clin
Immunol. 2008 Aug; 122 (2 Suppl): pp. 1—84).
Fluticasone is an active ingredient from the
corticosteroid class and is used for the treatment of
seasonal or' perennial allergic rhinitis. Formulations
on the market for nasal application are, for example,
Flutide, Flonase or Fluticasone Propionate Nasal Spray
2O 50 pg (Roxane Laboratories). In the suspensions, the
active ient fluticasone is present as a microfine
dispersion in the liquid.
ch shows, however, that more than 60% of patients
with allergic rhinitis are not satisfied with their
current treatment, ularly due to lack of efficacy
(Bousquet, J' Allergy" Clin. Immunol. 2009 Sep; 124(3):
428—33). Thus, there exists a need for improved
medicaments for the treatment of allergic is.
The object of the present invention is to jprovide a
corticosteroid—containing medicament for the treatment
of allergic rhinitis with improved efficacy, or to at
least e the public with. a useful choice. The
_ 3 -
object is achieved by means of a nasal ation of
fluticasone, particularly fluticasone propionate,
sing microcrystalline cellulose + Na
carboxymethylcellulose (Avicel CL 611), disodium
edetate, polysorbate 80, ine, benzalkonium
de and. phenylethyl alcohol as auxiliaries. The
nominal dose of fluticasone propionate is 50 pg.
In one aspect of the present invention, there is
provided a nasal pharmaceutical ation adapted to
be applied as droplets comprising fluticasone
nate, microcrystalline cellulose and Na carboxy—
methylcellulose (Avicel CL 611) as a suspension agent,
disodium edetate as a chelating agent, polysorbate 80
as a wetting agent, glycerol as an osmotically active
substance, and at least one preservative selected from
the group comprising konium chloride and
phenylethyl l, wherein the droplet size is
between 75 um and 95 pm, in half of the droplets in an
administered dose unit and wherein the formulation is
formulated for administration by means of a spray pump.
A critical parameter for the ency of locally
applied. and locally‘ acting substances is the nominal
dose of active ingredient administered. It is generally
assumed that drugs with the same nominal dose of the
same active ingredient show comparable effects
(LeSouef, Allergy 1999, 54, pp. 93—96).
3O The formulation according to the invention has the
advantage, compared to the prior art, that the
corticoid fluticasone has a better local availability
[followed by page 3a]
-3a...
in the nose despite the same nominal dose (Derendorf et
al., 2012 Br J Clin Pharmacol accepted) and can have a
stronger effect there.
Table 1 shows a comparison between the inventive
ation according t1) example 1. and a. formulation
from the prior art casone Propionate Nasal Spray
50 Mg (Roxane Laboratories)) using the same nominal
dose. The results are reported as the ence from
baseline unless indicated otherwise (rTNSS: reflective
Total Nasal Symptom Score; iTNSS: instantaneous Total
Nasal Symptom Score; TOSS: Total Ocular Symptom Score).
[followed by page 4]
Parameter Inventive Comparison
formulation (Fluticasone
50 pg from
rTNSS —5.l —3.8
iTNSS -4.60 —3.46
rTOSS —2.71 —2.17
Nasal tion —1.10 -O.86
Nasal itching —l.lO —o.91
Ocular itching —O.96 —o.7o
Watery eyes ~O.96 —0.82
rTNSS (baseline —5.42 —4.76 —__—_+
>18.9) __—L____
rTNSS (blocker) ~4.95 —3.92
Nasal congestion —l.26 -O.9O
(blocker)
Table 1
Compared to before treatment, the nasal and ocular
symptom scores and also the individual complaints
decrease more distinctly than with conventional
fluticasone nasal spray at the same nominal dose. While
tional fluticasone alters the overall score of
the four relevant nasal symptoms (nasal congestion,
sneezing, runny nose, nasal itching) on average by only
3.8 points on a scale of O to 24 during 14—day therapy
(Hampel et al., Ann Allergy Asthma Immunol. 2010; 105:
pp. 168—73), the new formulation. performs distinctly
better at 5.1 points (Carr et al. J .Allergy Clin
Immunol 129(5) 2012 pp. 1282—1289).
— 5 -
efficacy depends on
As mentioned above, the superior
the active
better local availability of ingredient
systemic
which is reflected in the better
available fluticasone
bioavailability. The systemically
mainly absorbed through the nasal
must have been
1%. The
mucosa, since oral tion. is only‘ about
6-sequence, 3—
In one of two randomized, 3—period,
treatment crossover studies, 19 healthy volunteers were
200 ug of
each once intranasally administered
fluticasone (nominally 50 in each nostril)
ug, 2 sprays
tional standard (Fluticasone Propionate Nasal
(Roxane Laboratories)) and in the inventive
Spray 50 ug
1. Serum
formulation (new) ing to e
fluticasone was measured over 24 hours. The mean
fluticasone levels in [pg/ml] are plotted against time
of in the
in Figure l and show the degree improvement
availability.
Further embodiments of the invention comprise, in place
pharmaceutically acceptable ester
of asone or a
from
or salt thereof, one or more active ingredients
of intranasal corticosteroids consisting of
the group
budesonide, beclomethasone, mometasone, inolone,
thasone, ciclesonide or pharmaceutically
acceptable salts or esters thereof.
one or more
The formulation optionally comprises
auxiliaries from the group of suspension
agents/thickeners, such as carboxymethylcellulose,
hydroxymethylcellulose, cellulose, gelatine,
polyvinylpyrrolidone, polyethylene glycol, polyvinyl
WO 63501 — 6 ~
alcohol, preferably microcrystalline cellulose + Na
carboxymethylcellulose (Avicel CL 611), chelating
agents, preferably disodium edetate, wetting agents
such as polyoxyethylene derivatives of fatty acids or
polyoxyethylene derivatives of partial fatty acid
esters of sorbitol anhydrides, preferably" polysorbate
80, osmotically active substances such as sucrose,
glucose, sorbitol, propylene glycol, NaCl, preferably
glycerol, and. also preservatives such. as thiomersal,
benzyl alcohol, alkonium and. konium salts,
chlorhexidine ate, preferably benzalkonium
chloride and phenylethyl alcohol.
The preparation of the formulation according to the
invention is carried out, for example, by heating
purified water to 30 — 40°C. Disodium edetate and
glycerol then sively added and both are mixed are
min. Microcrystalline cellulose and Na
for ca. 5
carboxymethylcellulose sieved through a 40 mesh
then added with stirring and the mixture
sieve and are
is r stirred for ca. 30 min.
with
a separate vessel, polysorbate 80 is stirred
purified water for ca. 5 min. Fluticasone propionate is
added with further stirring and the e is r
stirred for ca. 30 min.
further mixed
The two dispersions are combined and are
min. Benzalkonium chloride solution 10%
for ca. 10
(w/v) is added and the mixture is mixed by stirring for
ca. 10 min.
is mixed
Phenylethyl alcohol is added and the mixture
ng for 10 min. After addition of purified
by ca.
— 7 —
for ca. 30 min.
water, the suspension is homogenized
and is passed through a 200 mesh sieve.
The administration. of the formulation is effected. by
with commercially available pumps, such
spray bottles
as those front Aptar or MeadWestvaco Corporation.
VP3/l4OF CSZO—AG pump from Aptar is particularly
preferred.
the invention is d
The formulation according to
with 150
a droplet size of no more than um, preferably
between 50 um and 100 um, particularly preferably
between 75 um and 95 um, in half of the droplets in the
administered dose unit.
dose unit comprises between 10 and 200
One pg,
preferably between 25 and 100 ug, particularly
ably between. 40 and 60 ug of intranasal
osteroid. One dose unit comprises, for example,
50 pg of asone propionate.
corticosteroid
The dose unit of the intranasal is
administered in a volume between 50 and 250 pl,
100 and 150 pl. A dose unit of
preferably' between
for example, in
asone propionate is administered,
a volume of 137 pl per spray.
once or twice
1—2 administered
sprays per nostril are
daily and therefore in total 2-8 sprays per day;
ular preference is given to administering l spray
nostril
in the morning and l spray in the evening per
and therefore in total 4 sprays per day.
- 8
Examples:
example
The following compositions are listed by way of
without restricting the invention.
Example 1:
ient Amount
[9/100 g]
'— ’1
Fluticasone 0.0365
propionate
MCC+NaCMC* * 2 . o o
(Avicel CL
611)
Disodium 0.01
edetate
L————*—*————*—*—*r—*—~—————fi
Polysorbate 80 0.005
L— i
Glycerol 2.30
Benzalkonium 0.01
chloride
t_ n
Phenylethyl 0.25
alcohol
Purified water to 100
L L
e 2:
Ingredient
Fluticasone
'——“—,'—’_‘_-_‘_—__~—‘-—-l
proplonate
L______l_________fi.__l_.__l__J
MCC+NaCMC** 2.00
(Avicel CL
611) \
um 0.01
edetate
ral§cerol I_§—.30 _1
Benzalkonium 0.01
chloride
4 1
Phenylethyl 0 .25
alcohol
réurified water to 100
[_______________—.—————
Claims (1)
- Claims A nasal pharmaceutical formulation adapted to be applied as droplets comprising asone propionate, microcrystalline cellulose and Na carboxy—methylcellulose (Avicel CL 611) as a suspension agent, disodium edetate as a chelating agent, polysorbate 80 as a wetting agent, glycerol as an cally active substance, and at least one preservative selected from the group 10 sing konium chloride and. phenylethyl alcohol, wherein the droplet size is between 75 pm and 95 pm, in half of the droplets in an administered dose unit and wherein the formulation is formulated, for administration. by means of a 15 spray pump. The use of a formulation as claimed in claim 1 in the cture of a medicament for prophylaxis or treatment of allergic seasonal or perennial 20 is or rhinoconjunctivitis. The formulation as claimed in claim 1, substantially" as herein. described. with. reference to the
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DE102011103347.9 | 2011-05-27 | ||
DE102011103347.9A DE102011103347B4 (en) | 2011-05-27 | 2011-05-27 | Nasal pharmaceutical formulation |
PCT/EP2012/002222 WO2012163501A1 (en) | 2011-05-27 | 2012-05-24 | Nasal pharmaceutical formulation |
Publications (2)
Publication Number | Publication Date |
---|---|
NZ616149A NZ616149A (en) | 2015-11-27 |
NZ616149B2 true NZ616149B2 (en) | 2016-03-01 |
Family
ID=
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP5683719B2 (en) | Bepotastine composition | |
JP5524438B2 (en) | A novel combination of loteprednol and antihistamines | |
US20110189106A1 (en) | Intranasal compositions, dosage forms and methods of treatment | |
US7378082B1 (en) | Method for treating allergic rhinitis without adverse effects | |
PL208686B1 (en) | Compositions for treatment of common cold | |
US9675624B2 (en) | Combination of levocabastine and fluticasone furoate for the treatment of inflammatory and/or allergic conditions | |
AU2012265231B2 (en) | Nasal pharmaceutical formulation | |
JP2011507895A (en) | Enhanced light stabilization of oxymetazoline | |
NZ616149B2 (en) | Nasal Pharmaceutical Formulation Comprising Fluticasone | |
US20080194544A1 (en) | Aqueous formulations of epinastine for treating allergic rhinitis | |
JP2002161032A (en) | Composition applied to mucous membrane | |
RU2798030C2 (en) | Treatment of allergic rhinitis in pediatric category using a combination of mometasone and olopatadine | |
JP7391026B2 (en) | Treatment of allergic rhinitis in pediatric subjects using a combination of mometasone and olopatadine | |
WO2008098122A2 (en) | Method for treating allergic rhinitis without adverse effects | |
EA037259B1 (en) | Use of a fixed dose pharmaceutical composition comprising mometasone and azelastine in treating allergic rhinitis and method of treating allergic rhinitis | |
JP2002322060A (en) | Composition for application to mucous membrane |